Nei Podcast

What are the hypothesized neurobiological mechanisms that support the use of cannabidiol (CBD) as a treatment for opioid use disorder (OUD)? How does CBD influence cue-induced craving in OUD? What are the challenges and opportunities in further exploring the use of CBD as a potential treatment for OUD? Dr. Joji Suzuki is the Director of the Division of Addiction Psychiatry and Director of Addictions Education in the Department of Psychiatry, Brigham and Women’s Hospital, and an Assistant Professor of Psychiatry at Harvard Medical School. His areas of clinical and research interests are the assessment and management of substance use disorders and related conditions in general medical settings, motivational interviewing, office-based opioid treatment, implementation of collaborative models of care, and medical education. He is the site director for the Partners Addiction Psychiatry Fellowship, and is involved with teaching medical students, residents, and allied health professionals. He has authored over 30 p

In this episode, Dr. David Goodman addresses your unanswered questions from his presentation, Setting the Mood: Strategies for Diagnosing and Treating ADHD in the Context of Bipolar Disorder, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. Manpreet Singh addresses your unanswered questions from her joint presentation, Don’t Get Mixed Up! Recognizing and Treating Mixed Features Across the Lifespan, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. Dani Cabral addresses your unanswered questions from her presentation, Memories in the Future: An Update on the Diagnosis and Treatment of Alzheimer’s Disease, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

In this episode, Dr. Sarah Vinson addresses your unanswered questions from her panel presentation, Serious Mental Illness: A Collaborative Approach, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

How does dysfunction in cognition affect overall treatment outcomes for psychiatric disorders? What are the challenges in treating cognitive deficits in psychiatric conditions? What treatments are in development for cognitive dysfunction? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the “untreatable” dimensions of psychopathology. Today, Dr. Andy Cutler interviews Dr. Richard Keefe and Dr. Stephen Stahl about the clinical difficulties of treating cognitive dysfunction.  Let’s listen to Part 2 of our theme: Untreatable Dimensions of Psychopathology. Subscribe to the NEI Podcast, so that you don’t miss another episode! ***Register today for the 7th annual NEI Synapse, being held April 19th through the 21st in-person in Las Vegas and online via simulcast. Use discount code PODCAST to save $100 on your registration at nei.global/Synapse.

What are some common challenges faced by caregivers of individuals with dementia? What is comprehensive dementia care and how does it improve quality of life of individuals with dementia and their caregivers? What is the GUIDE Model and why is it needed?  Carolyn Clevenger, DNP, RN, GNP-BC, AGPCNP-BC, FAANP, FGSA is a Professor at the Nell Hodgson Woodruff School of Nursing at Emory University. Dr. Clevenger is a nationally recognized educational leader in advanced practice nursing and in geriatrics and gerontology. She is a Past President of the Gerontological Advanced Practice Nurses Association, Fellow of the American Association of Nurse Practitioners (AANP) and the Gerontological Society of America, and contributor to the AANP Certification Program. She is the director of the nurse-led patient centered medical home for people living with dementia, the Integrated Memory Care Clinic (IMCC). IMCC represents an innovative clinical model that provides memory and primary care in a single integrated model fo

What is the role of mindfulness techniques in the treatment of anxiety disorders and how is it evolving? How does mindfulness-based stress reduction compare to pharmacological treatment for anxiety disorders? What are the hypotheses that have been made about why mindfulness-based treatments work for anxiety? Elizabeth Hoge, MD is a Professor and Director of the Anxiety Disorders Research Program in the Department of Psychiatry at Georgetown University School of Medicine. Dr. Hoge completed her psychiatry residency training and research fellowship at the Massachusetts General Hospital in Boston. During her research fellowship, she earned a Masters in Medical Science from the Harvard Medical School-Massachusetts Institute of Technology program in Health Sciences and Technology with a focus on clinical trials. Her research focuses on treatments for anxiety disorders, including medication, psychotherapy and mindfulness, and the examination of biomarkers of anxiety, stress, and trauma. She has over 50 publicatio

What are the cultural factors that should be considered when providing mental health care to migrant and refugee populations? What challenges and opportunities exist in providing mental health care to these communities? How can mental health professionals collaborate with other disciplines to create a holistic approach to address the mental health needs of migrant and refugee populations?  Lisa Fortuna, MD, MPH is the Chief of Psychiatry and Neurosciences at the Riverside School of Medicine. She was the Chief of Psychiatry and Vice-Chair at Zuckerberg San Francisco General Hospital/UCSF and Associate Professor of Clinical Psychiatry. She has been an investigator on several National Institutes of Health and foundation-funded studies of Latino and immigrant mental health, integrated care, access to care including a principle investigator of a NIMH funded R01 aimed at optimizing family navigation for addressing child behavioral health in primary care and a Patient Centered Outcome Research Institute (PCORI) f

How does anhedonia impact the overall treatment plan for patients with major depressive disorder and other psychiatric conditions? What are some of the most challenging aspects of treating anhedonia in patients? Are there any new treatments in development that may be helpful for treating anhedonia? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the “untreatable” dimensions of psychopathology. Today, Dr. Andy Cutler interviews Dr. Vladmir Maletic and Dr. Stephen Stahl about the clinical difficulties of treating anhedonia  Let’s listen to Part 1 of our theme: Untreatable Dimensions of Psychopathology. Subscribe to the NEI Podcast, so that you don’t miss another episode!

During Black History Month, we revisit an enlightening conversation with Dr. Sarah Vinson about the impact of structural racism on Black mental health and how mental healthcare providers can make a difference in the lives of patients by leveraging their privilege and skillsets.  Dr. Sarah Y. Vinson is a physician who is triple-board certified in adult, child & adolescent, and forensic psychiatry. She is the founder of the Lorio Psych Group, an Atlanta, GA based mental health practice providing expert care and consultation. Dr. Vinson is also the founder of Lorio Forensics, which provide consultation on a wide variety of cases in criminal, civil, and family court cases. After graduating from medical school at the University of Florida with Research Honors and as an Inductee in the Chapman Humanism Honors Society, she completed her general psychiatry training at Cambridge Health Alliance/Harvard Medical School. While there, she also received specialized training in trauma through the Victims of Violenc

Can the therapeutic benefits of psilocybin be achieved without a psychedelic trip? What is the role of psychological support in the therapeutic effect of psilocybin? What is microdosing and what are its potential benefits and risks? What is the path to FDA approval and commercialization of psilocybin and other psychedelics?  Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the role of psychedelics in modern psychiatry.  Today, Dr. Andy Cutler interviews Dr. Charles Raison and Dr. Stephen Stahl about the importance of the psychedelic trip for the therapeutic benefits of psilocybin.  Let’s listen to Part 4 of our theme: Classic Psychedelics for the Modern Psychopharmacologist.  Subscribe to the NEI Podcast, so that you don’t miss another episode! 

The climate crisis has a wide-reaching impact that negatively affects both acute and long-lasting mental health outcomes. Are there specific populations that are more vulnerable to mental health issues related to the climate crisis? What is the role of mental health professional to combat the negative influence of climate change on mental health? Robin Cooper, MD, is a psychiatrist who has had a private practice in San Francisco for 40 years, is Associate Clinical Professor in the Department of Psychiatry and Behavioral Sciences at the UCSF Medical School, where she is actively involved in efforts to address climate change impacts on mental health and health. She is co-founder of Climate Psychiatry Alliance, a national group of psychiatrists and mental health professionals dedicated to understanding, educating, and advocating about the specific impact of climate change on mental health. As she moves into semi-retirement in her clinical work, her work around climate change impacts on health and mental healt

In this CME episode, Dr. Andrew Cutler interviews Dr. Dani Cabral about current and novel diagnostic tools and treatments for Alzheimer’s disease. Optional CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CE credit, click nei.global/POD23-MDD Learning Objectives: After completing this educational activity, you should be better able to: Describe the potential role of multimodal imaging and biomarker strategies in the diagnostic process for Alzheimer’s disease Assess the safety and efficacy of novel disease-modifying pharmacological treatments for Alzheimer’s disease Describe potential future advancements in the diagnosis and treatment of Alzheimer’s disease Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (A

What do the clinical trials of psilocybin and other psychedelics show in terms of efficacy and safety? How much of the benefit with psychedelic treatment is attributable to psychological support? Is the psychedelic trip important for the therapeutic benefits of psychedelic treatments? Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the role of psychedelics in modern psychiatry. Today, Dr. Andy Cutler interviews Dr. Scott Aaronson and Dr. Stephen Stahl about the potential indications and therapeutic benefits of psilocybin and other psychedelics. Let’s listen to Part 3 of our theme: Classic Psychedelics for the Modern Psychopharmacologist. Subscribe to the NEI Podcast, so that you don’t miss another episode!

In this CME episode, Dr. Andrew Cutler interviews Dr. Jeffrey Strawn about the role of pharmacogenomic testing in guiding treatment of major depressive disorder (MDD). They discuss how pharmacogenomic testing works, the impact of failed treatments and side effects on patients with MDD, and the clinical applications and future directions of pharmacogenomic testing. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-GEN Learning Objectives: After completing this educational activity, you should be better able to: Recognize the role of a patient’s genetics in informing the efficacy and tolerability of antidepressants Consider opportunities to use pharmacogenomics as an evidence-based tool that can be employed to inform clinical decision making Implement pharmacogenomic testing to optimize patient outcomes, including symptom improvement, medication response, and remission rate Accreditat

What were some new treatments approved by the FDA? What did we learn about the long-term safety of methylphenidate in childhood ADHD? Are there benefits to long-term maintenance treatment with antidepressants in bipolar disorder? What did we learn about the safety and efficacy of subcutaneous racemic ketamine for treatment-resistant depression and MDMA for PTSD? In this episode, Dr. Andrew Cutler and Dr. Roger McIntyre address these questions and so much more about this past year in psychopharmacology.   Dr. Roger S. McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function, and medical comorbidity. His w

In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about the impact of residual symptoms on patients with major depressive disorder, as well as treatment modifications to address residual symptoms in these individuals. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-MDD Learning Objectives: After completing this educational activity, you should be better able to: Describe the burden of residual symptoms in patients with major depressive disorder (MDD) Implement measurement-based care to assess residual MDD symptoms Modify treatment strategies to address residual MDD symptoms, including cognitive impairment, anhedonia, emotional blunting, and sexual dysfunction Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation C

In this episode, Dr. Vladimir Maletic addresses your unanswered questions from his presentations, “From Despair to Delight: Advances in the Diagnosis and Treatment of Anhedonia” and “Ho Hum to Aha! Treating Anhedonia and Emotional Blunting.”

In this episode, Dr. Leslie Citrome addresses your unanswered questions from his presentation, There’s No Place Like Home: Addressing Agitation in Dementia.